Nurix Therapeutics Inc officer Christine Ring filed a Form 144 notice on November 3, 2026, disclosing a proposed sale of 6,113 shares of common stock with an aggregate market value of $157,104.10, to be executed on NASDAQ through Morgan Stanley Smith Barney LLC.

Key Highlights

  • Proposed sale: Christine Ring, an officer of Nurix Therapeutics Inc, plans to sell 6,113 shares of common stock with an aggregate market value of $157,104.10.
  • Source of shares: The 6,113 shares were acquired on October 30, 2025, from the issuer via restricted stock units, with payment dated October 30, 2025.
  • Approximate sale date: The filing lists November 3, 2026 as the approximate date of sale on NASDAQ.
  • 10b5-1 plan: The notice indicates reliance on a Rule 10b5-1 plan adopted on November 10, 2025.
  • Shares outstanding: The filing states 109,249,814 shares of common stock were outstanding at the time of the notice.
  • Prior three-month sales: Ring sold a total of 22,175 shares in four separate 10b5-1 transactions between September 2 and November 2, 2026, generating gross proceeds of $557,208.61 in aggregate.

Christine Ring's Proposed Share Sale Under a 10b5-1 Plan at Nurix Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 3, 2026, Christine Ring, identified as an officer of Nurix Therapeutics Inc (NASDAQ:NRIX), intends to sell 6,113 shares of the company's common stock. The filing lists an aggregate market value of $157,104.10 for the proposed sale, to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY 10004.

The shares proposed for sale were acquired on October 30, 2025, through restricted stock units granted by the issuer. The filing notes that the nature of payment for those units is listed as "N/A," consistent with the RSU structure. Ring's Form 144 also indicates reliance on a written trading plan adopted under Rule 10b5-1 on November 10, 2025, with the notice dated November 3, 2026.

The filing also discloses sales made by Ring during the prior three months under 10b5-1 plans. Those transactions included sales of 5,786 shares on November 2, 2026 (gross proceeds $149,127.79), 4,816 shares on November 2, 2026 (gross proceeds $124,859.29), 5,786 shares on October 2, 2026 (gross proceeds $134,148.99), and 5,787 shares on September 2, 2026 (gross proceeds $149,072.54). The combined gross proceeds from those four prior transactions totaled $557,208.61, according to the filing. All transactions listed are described as 10b5-1 sales.

What Was Disclosed

The Form 144 notice discloses Christine Ring's proposed sale of 6,113 Nurix Therapeutics common shares valued at $157,104.10, acquired as restricted stock units, to be sold on NASDAQ under a 10b5-1 plan adopted November 10, 2025, alongside four prior three-month sales totaling 22,175 shares.